Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis

Clinical Rheumatology

Volumn 19, Issue 5, 2000, Pages 352-359

  Shimizu, T ^a   Tomita, Y ^a   Son, K ^a   Nishinarita, S ^a   Sawada, S ^a   Horie, T ^a  

^a NONE   (Japan)

Author keywords

Dermatomyositis; Polymyositis; Soluble TNF receptor 1; Soluble TNF receptor 2; TNF receptor 1; TNF receptor 2

Indexed keywords

CREATINE KINASE; CYCLOPHOSPHAMIDE; FRUCTOSE BISPHOSPHATE ALDOLASE; METHYLPREDNISOLONE; PREDNISOLONE; TUMOR NECROSIS FACTOR 1; TUMOR NECROSIS FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; MALE; MONONUCLEAR CELL; NORTHERN BLOTTING; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOTTING, NORTHERN; CHRONIC DISEASE; CREATINE KINASE; DERMATOMYOSITIS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRUCTOSE-BISPHOSPHATE ALDOLASE; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMYOSITIS; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033808162     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670070027     Document Type: Article

References (42)

1. The immunobiology of muscle
2. Mechanisms of inflammation and histopathology in inflammatory myopathy
3. Cellular immune mechanisms in inflammatory myopathies
4. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis
5. Impaired tumour necrosis factor-α (TNF-α) production and abnormal B cell response to TNF-α in patients with systemic lupus erythematosus (SLE)
6. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis
7. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies
8. Expression of tumor necrosis factor-α in muscles of polymyositis
9. Two TNF receptors
10. Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor
11. Molecular cloning and expression of a receptor for human tumor necrosis factor
12. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins
13. Expression of tumor necrosis factor receptor on human monocytes and internalization of receptor bound ligand
14. Shedding of tumor necrosis factor receptors by activated human neutrophils
15. Two types of TNF receptors are expressed on human normal and malignant B lymphocytes
16. Tumor necrosis factor (TNF) receptor expression in T lymphocytes, differential regulation of the type I TNF receptor during activation of resting and effector T cells
17. Characterization in vitro of a human tumor necrosis factor-binding protein, a soluble form of a tumor necrosis factor receptor
18. Characterization of a tumor necrosis α (TNF- α) inhibitor: Evidence of immunological cross-reactivity with the TNF receptor
19. Slow release of soluble TNF receptors by monocytes in vitro
20. A human inhibitor of tumor necrosis factor α
21. Purification and identification of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients
22. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus
23. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease; soluble TNFR-75 as a biological marker of disease activity
24. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity
25. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis
26. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatoid diseases
27. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
28. Polymyositis and dermatomyositis
29. Increased gene expression of TNF-α and IL-1β in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
30. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls
31. Local expression of cytokines in idiopathic inflammatory myopathies
32. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia
33. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo
34. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis
35. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice
36. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: A biologic marker of disease activity with a possible role in the lack of acute-phase protein response
37. Elevated serum levels of neoptelin in adult patients with polymyositis/dermatomyositis
38. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis
39. Adult-onset polymyositis-dermatomyositis: Description of 25 patients with emphasis on treatment
40. Idiopathic myositis: A rheumatological view
41. Inflammatory myopathy - Do we have adequate measures of the treatment response?
42. Cytokine inhibitors in autoimmune disease